——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Research & Development Wien (euro adhoc) – WHITEHOUSE STATION, N.J. and VIENNA, June 8, 2011 – Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Intercell AG (VSE: ICLL) today announced that following [...]
Tag Archive > Clinical Benefit
Amgen Receives CHMP Positive Opinion for XGEVA(TM) (Denosumab) in the European Union
Thousand Oaks, California (ots/PRNewswire) – Amgen today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a positive opinion for the marketing authorization of XGEVA(TM) (denosumab) for the prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in [...]
Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients
London and San Francisco (ots/PRNewswire) – AstraZeneca’s new oral syk inhibitor, fostamatinib (R788), recently in-licensed from Rigel Pharmaceuticals, Inc. , significantly improved outcomes of patients with rheumatoid arthritis (RA) who responded inadequately to ongoing treatment with methotrexate (MTX), according to phase II study data published in The New England Journal of Medicine today. In the [...]
Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent Atrial Fibrillation
Paris, May 12, 2010 (ots/PRNewswire) – Sanofi-aventis announced today the initiation of a multinational, randomized, double-blind Phase IIIb trial, PALLAS, to assess the potential clinical benefit of Multaq(R) (dronedarone) in over 10,000 patients with permanent atrial fibrillation (AF) to reduce major adverse cardiovascular events. The announcement was made during Heart Rhythm 2010, the Heart Rhythm [...]
New Study Demonstrates Patients With High-Risk MammaPrint Profile Benefit From Chemotherapy
HUNTINGTON BEACH, California, and AMSTERDAM, April 29, 2010 (ots/PRNewswire) — Today, at the 11th Annual Meeting of the American Society of Breast Surgeons, Agendia, a world leader in molecular cancer diagnostics, announced that Breast Cancer Research and Treatment has published an important study demonstrating the benefit of adjuvant chemotherapy for patients with a high-risk of [...]
Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
Paris, November 30 (ots/PRNewswire) – – First New Anti-Arrhythmic Drug to be Approved in the European Union in the Last 10 Years Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the European Commission has granted marketing authorization for Multaq(R) (dronedarone – 400mg Tablets) in all 27 European member states. This approval follows the European [...]
Boehringer Ingelheim to Commence Phase III Study Investigating the Role of BIBW 2992 (Tovok(TM)) as First-Line Treatment for Non-Small Cell Lung Cancer (NSCLC) Patients With EGFR Mutations
Ingelheim, Germany (ots/PRNewswire) – – Data From Phase II Studies Investigating BIBW 2992 (Tovok(TM)) and BIBF 1120 (Vargatef(TM)) in NSCLC Patients Presented at 13th World Conference on Lung Cancer (WCLC) INGELHEIM, Germany, August 3 /PRNewswire/ — Boehringer Ingelheim announced today at the International Association for the Study of Lung Cancer’s 13th World Conference on Lung [...]
FDA Approves Multaq(R) for Patients With Atrial Fibrillation or Atrial Flutter
Paris (ots/PRNewswire) – – Multaq(R) Approved to Reduce the Risk of Cardiovascular Hospitalization in Patients With Atrial Fibrillation or Atrial Flutter – U.S Commercial Launch Planned for the Summer of 2009 Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration (FDA) has approved Multaq(R) (dronedarone) 400 mg Tablets. Patients [...]
Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
Paris and Brisbane, California (ots/PRNewswire) – – Data Highlighted in Plenary Session of 2009 American Society of Clinical Oncology Annual Meeting Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and its fully owned subsidiary, BiPar Sciences, today announced results from a randomized Phase 2 clinical trial of BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor, in combination with [...]
Nimotuzumab Demonstrates Efficacy In Randomized Head & Neck Cancer Study Without The Toxicities Associated With Other EGFR Drugs
(pressebox) Mississauga, Canada, 02.06.2009, YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that results from a randomized trial of nimotuzumab (aka BIOMAb/TheraCIM/h-R3) in patients with inoperable, locoregionally advanced Stage III/IVa head and [...]
Avastin Plus Commonly Used Chemotherapies Improves the Time Breast Cancer Patients Live Without Their Disease Getting Worse
Basel, Switzerland (ots/PRNewswire) – – RIBBON-1 Study Confirms Benefit of Avastin in Treating HER2-Negative Breast Cancer – For Non-US, Non-UK and Non-Austrian Media Results from the phase III RIBBON-1 study presented today at ASCO showed that patients with advanced HER2-negative breast cancer who were treated with Avastin(R) (bevacizumab) plus the most commonly used chemotherapies lived [...]
